ERBB2 and gastroesophageal junction adenocarcinoma: Based on the DESTINY‐Gastric01, TXd was also approved in 2021 for the treatment of locally advanced or metastatic HER2‐positive gastric or gastroesophageal junction adenocarcinoma in patients who had received a prior trastuzumab‐based regimen.